21st ANNUAL ENETS But what of treatments and innovations? I hear you ask! NETs: Ongoing work regarding somatostatin analogues - improving de currently in phase III study in acromegaly (NCT05192382) and Phase reducing flushing and bowel movements - as yet to assess anti-tumou A randomised trial of PEN-221 for midgut NETs is in development, DE (meaning 4 injections/yr rather than 13 - if on a 28 day cycle) - the OX CAM2029 a novel, ready-to-use, long-acting, slow release Octreotide LAR or lanreotide autogel in patients with advanced, well-differentiated And the potential for Octreotide hydrogel implants? (trialled in acrome NECs: traditionally treated first line with Platinum-based chemotherap This remains a recommended first-line option - however, there have b following this: NCT05058651 : phase II/III study evaluating the addition of the Atezoli carcinomas that originate outside the lung. NCT06102746: aims to explore whether the combination of surufatinib treatment for patients with advanced gastric neuroendocrine carcinom NCT02687958 : Study of Everolimus as Maintenance Therapy for Meta 2nd line therapies: including BEVANEC, NETTER-2 (CLICK HERE TO randomised study in second-line treatment. From initial studies, Immunotherapy alone, or even in combination, ma Chemotherapy + DUAL Immunotherapy. New targets e.g. DLL3: researchers have found expression of DLL3 in DAREON-5: A study to test whether different doses of BI 764532 help NCT04471727 : A study in patients with advanced cancers associated A special post-ENETs 2024 focused Webi-Natter will take place in Apr the event to catch up on the recording.
8
Made with FlippingBook flipbook maker